Healthcare Industry News: antiviral
News Release - October 4, 2010
New American Therapeutics Acquires Antiviral Drug Denavir(R)CRANFORD, N.J., Oct. 4 -- (Healthcare Sales & Marketing Network) -- New American Therapeutics, Inc., announced today that it acquired all U.S. rights to manufacture, market and sell the antiviral topical drug Denavir® owned by Novartis. Denavir (1% penciclovir cream) is a highly selective and potent topical antiviral treatment indicated for the treatment of recurrent herpes labialis (cold sores) in adults and children 12 years of age and older. The topical antiviral cream market in the U.S. is valued at approximately $100 million annually.
Novartis has agreed to provide limited transitional services to New American Therapeutics to allow for a smooth transition of the business to New American Therapeutics.
"Denavir offers patients a proven therapy for the treatment of herpes labialis. Likewise, the established revenue stream will provide New American Therapeutics with the capital required to expand our growing infrastructure and product line," stated Alan L. Rubino, CEO and President of New American Therapeutics. "We are enthusiastic about advancing the commercial efforts of this important asset."
Denavir 1% penciclovir topical cream is a safe and effective medicine when used as directed. Patients should read the package directions before using Denavir. Possible side effects include headache or irritation at the site of application. Patients should contact their doctor if they experience these symptoms as a result of using Denavir. Patients should consult their doctor before using 1% penciclovir topical cream if they are allergic to penciclovir or acyclovir (Zovirax®), or any other drugs, or are pregnant or nursing.
About New American Therapeutics, Inc.
New American Therapeutics, Inc. is a privately held, specialty pharmaceutical company based in Cranford, N.J. that acquires, markets and develops products in select therapeutic areas.
Source: New American Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.